Format

Send to

Choose Destination
J Peripher Nerv Syst. 2015 Dec;20(4):397-402. doi: 10.1111/jns.12147.

Anti-TNF alpha medications and neuropathy.

Author information

1
Nerve-Muscle Unit, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
2
Division of Neurology, Department of Clinical Neurosciences, University Hospital of Geneva (HUG), Geneva, Switzerland.
3
Department of Rheumatology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
4
Department of Neurology, Basel University Hospital, Basel, Switzerland.

Abstract

We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti-tumor necrosis factor alpha (a-TNF) medications-induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a-TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person-years. The median time from a-TNF medication treatment to ATIN was 16.8 months (range 2-60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a-TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was "inflammatory", suggesting that it could be due to systemic pro-inflammatory effects of a-TNF agents.

KEYWORDS:

anti-TNF alpha; demyelination; inflammation; neuropathies

PMID:
26309233
DOI:
10.1111/jns.12147
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center